Nanobiotix

Nanobiotix

Laurent Levy and colleagues founded Nanobiotix in Paris in 2003 to build a company around a physical mechanism that had not been applied systematically to oncology—elevating radiation dose within cancer cells without raising toxicity in surrounding tissue. The firm spent its first decade on preclinical and early clinical work, gradually collecting data showing that its inert hafnium oxide nanoparticles, injected directly into a tumor, absorb ionizing radiation and re-emit it as a cloud of electrons that tear apart cancer cell DNA. The company listed on Euronext in 2012 and later secured a secondary listing on Nasdaq. The firm's strategy has centered on establishing NBTXR3 as a universal radioenhancer, not a single-indication drug. Trials span soft tissue sarcoma—which earned a CE mark in 2019 allowing European commercialization—head and neck cancers, lung, esophageal, pancreatic, and other solid tumors where radiotherapy is standard of care. The company places equal weight on immunotherapeutic combinations, testing whether radiation-amplified cell death produces an abscopal effect that primes tumors for checkpoint inhibitors. In 2019, Nanobiotix signed a global licensing agreement with Janssen Pharmaceuticals for NBTXR3 across multiple solid-tumor indications outside Asia (per Nanobiotix, 2019). The collaboration expanded in 2023 with a $25 million upfront payment and a $43 million equity investment from Johnson & Johnson Innovation, alongside an amended co-development framework (per company communications, July 2023). A concurrent joint strategic collaboration with The University of Texas MD Anderson Cancer Center, announced September 2023, covers a multi-arm clinical development program spanning several tumor types. Nanobiotix maintains its headquarters in Paris and a US office in Cambridge, Massachusetts. The company reports headcount on a consolidated basis in its annual filings; while current team size is not independently confirmed, historically its operations have been sized for a single-product, capital-efficient development model. The firm has not disclosed an in-house investment vehicle or family-office structure, functioning instead as a public biotech whose capital allocation is governed by a board and executive management. The MD Anderson and J&J agreements, reached within weeks of each other in 2023, constituted the most operationally significant period in the company's history since the original CE mark, setting up NBTXR3 for simultaneous exploration across multiple organ sites. The firm's structural differentiator is its asset being a physical device rather than a biologic or small molecule. Because NBTXR3 does not interact chemically with any cellular pathway, its safety profile depends on injection precision rather than systemic toxicity, and it is likely to resist the tumor-mutation escape that complicates targeted therapies. That physics-based universality allows Nanobiotix to advance one product through dozens of registrational trials and partnerships without the typical pharmaceutical need to build a molecule-by-molecule pipeline.